1 Transcriptomic signature on Hantavirus Cardiopulmonary Syndrome

2 patients, reveals an increased interferon response as a hallmark of critically ill

3 patients

- 4
- 5 Grazielle E. Ribeiro¹, Eduardo Duran-Jara¹, Ruth Perez¹, Analia Cuiza¹, Luis E. Leon²,
- 6 Constanza Martínez-Valdebenito³, Nicole Le Corre³, Marcela Ferres³, Leonila Ferreira⁴, Maria
- 7 Luisa Rioseco⁵, Jorge Gavilán⁶, Francisco Arancibia⁶, Jerónimo Graf⁷, Rene Lopez⁷, Jose Luis
- 8 Perez⁸, Mario Calvo⁹, Gregory J Mertz¹⁰, Pablo A.Vial^{1,11}, Cecilia Vial^{1*} and the hantavirus
 9 study group.
- ¹⁰ Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana
 ¹¹ Universidad del Desarrollo, Santiago, Chile
- 12² Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de
- 13 Chile, Santiago, Chile
- 14³ Departamento de Enfermedades Infecciosas e Inmunología Pediátricas, Pontificia Universidad
- 15 Católica de Chile, Santiago, Chile
- ¹⁶ ⁴Hospital Dr. Guillermo Grant Benavente Concepción, Concepción, Chile
- 17⁵ Hospital Puerto Montt Dr. Eduardo Schütz Schroeder, Puerto Montt, Chile
- 18 ⁶ Instituto Nacional del Tórax, Santiago, Chile
- 19⁷ Departamento de Paciente Crítico, Clínica Alemana de Santiago, Santiago, Chile
- 20⁸ Hospital Base San José de Osorno, Osorno, Chile.
- ²¹ ⁹ Instituto de Medicina, Universidad Austral de Chile Hospital Base Valdivia, Valdivia, Chile.
- 22 ¹⁰ Department of Internal Medicine, University of New Mexico, Albuquerque, USA
- 23 ¹¹ Departamento Pediatría Clínica Alemana de Santiago, Santiago, Chile
- 24
- 25 * Correspondence: mcvial@udd.cl; Tel.: +56225-785-772.
- 26
- 27 Short Title: Transcriptome analysis in HCPS patients
- 28
- Abstract: New World hantaviruses are important human pathogens that can cause a severe zoonotic disease called hantavirus cardiopulmonary syndrome (HCPS). HCPS patients can progress quickly to a severe condition with respiratory failure and cardiogenic shock that can be fatal in 30% of the cases. The role of the host's immune responses in this progression towards HCPS remains elusive. In this study, 12 patients hospitalized with severe HCPS were analyzed using a transcriptome approach combined with clinical laboratory data to gain a better insight into factors associated with a severe clinical course. Patients were further classified in two levels

of severity, a first group that required mechanical ventilation and vasoactive drugs (VM+VD) and a second group that also needed ECMO or died (ECMO/Fatal). Their transcriptional profile was compared during acute (early and late) and convalescent phases. Our results showed that overexpression of the interferon response is correlated with a worse (ECMO/Fatal) outcome and an increased viral load and proinflammatory cytokines in the early-acute-phase. This report provides insights into the differences in innate immune activation between severe patients that associates with different clinical outcomes, using a non-biased approximation.

43

44 Author Summary: Hantavirus are rodent-borne zoonotic pathogens that when transmitted to humans cause two diseases: hantavirus renal syndrome in Europe and Asia, and hantavirus 45 46 cardiopulmonary syndrome (HCPS) in the Americas. The latter, the goal of this work, is a highly lethal disease with a case fatality rate of 30%. Moreover no specific treatment or vaccine 47 is available for this disease. In this study, we analyzed hospitalized HCPS patients with severe 48 disease, to understand how they respond to hantavirus infection. We used a method that can 49 measure every mRNA that is being transcribed in one moment (transcriptome analysis) and thus 50 provide an accurate idea of how cells (specifically peripheral blood mononuclear cells) are 51 responding to infection. The knowledge gained in this study helps us further understand the 52 pathogenesis of this disease and might help us to design specific therapies to treat it. 53

54

55 Introduction

56

57 *Orthohantavirus* (known as hantaviruses) is a family of single-stranded, enveloped, 58 negative-sense RNA viruses that belong to the *Hantaviridae* family of the order *Bunyavirales[1]*.

2

59 Pathogenic Orthohantaviruses can cause two severe human zoonotic diseases: hemorrhagic fever with renal syndrome (HFRS) in Europe and Asia and hantavirus cardiopulmonary syndrome 60 (HCPS) on the American continent, with a case fatality rate up to 30% [2]. Andes 61 orthohantavirus (ANDV) is one of South American HCPS causing hantavirus and the only 62 hantavirus that is known to transmit from person to person [3,4]. After an individual gets 63 infected, the incubation period lasts from seven to 42 days [5,6]. Then a prodromal phase of 64 three to six days starts characterized by nonspecific symptoms including fever, headache and 65 myalgia. Patients may progress to the cardiopulmonary phase which in severe disease is 66 characterized by respiratory symptoms that start with dry cough and evolve to respiratory failure 67 needing mechanical ventilation due to a massive capillary leak into the lung interstitium [7,8]. 68 Severe patients present with circulatory shock and cardiovascular depression that require use of 69 vasoactive drugs [7,9]. Since there is not a vaccine for this deadly disease nor a specific 70 treatment, treatment is based on critical care support. A proportion of these severe patients have 71 a more critical illness that needs extracorporeal membrane oxygenation (ECMO) support and 72 about one third die. 73

A common hallmark of HCPS is the increased immune activation and vascular 74 75 permeability that develops during the cardiopulmonary phase producing pulmonary edema and cardiogenic shock in the most severe cases [7]. Viremia is present during the incubation period 76 for up to two weeks before onset of symptoms or appearance of IgM and IgG antibodies [3]. 77 78 Orthohantaviruses systemically infect and replicate predominantly in endothelial cells (ECs) [10,11], but can also infect epithelial and immune cells such as monocytes/macrophages and 79 dendritic cells [10,12–18]. Hantaviruses do not cause a cytopathic effect [10,11] suggesting that 80 81 their pathogenic effects are caused rather by the host immune response during infection, which

⁸² includes a cytokine storm [19]. Increased serum levels of proinflammatory cytokines, such as ⁸³ IL-6, IFN- γ and TNF- α , along with high infiltration of mononuclear cells, mainly CD4⁺ and ⁸⁴ CD8⁺ T lymphocytes in the lung, are associated with a severe outcome [20–22].

The innate immune response, which is the first reaction to a viral infection, could be one crucial step that modifies how the infected individual will respond to the virus. The regulation of the complement system, a significant component of innate immunity, could also influence the clinical course since deletion in regulatory genes (CFHR1 and CFHR3) have been found to be more frequent in severe HCPS patients [23].

The role of the host's immune responses in the progression of HCPS and their association with severity remains elusive. In this study, we applied a non-biased, transcriptome approach combined with clinical laboratory data in a cohort of ANDV-infected patients that developed a severe clinical course to explore the factors associated with HCPS severity.

This report provides a comprehensive description of innate immune programs active in PBMCs during acute HCPS patients. Increased type I IFN response, specifically the overexpression of interferon-induced genes (ISGs), is associated with a more severe outcome, defined as patients requiring ECMO or died, and to increased viral load in Peripheral Blood Mononuclear Cells (PBMCs) and increased proinflammatory cytokines levels in serum.

99

100 Results

101

102 Characterization of studied participants

103

104 Twelve patients, nine males and three females, with severe HCPS were analyzed in this

105 study. They had a median age of 27, nine being of European ancestry and three with Amerindian ancestry. The 12 HCPS patients were further reclassified into two groups according to their 106 severity: MV+VD (n=5) were those who received mechanical ventilation (MV) and vasoactive 107 drugs (VD) as treatment, and ECMO/Fatal (n=7) were those patients that also received ECMO as 108 a treatment or died. The healthy control group (n=9) consisted of four females and five males 109 with a median age of 25 years. There was no difference between groups when comparing 110 demographic data (Table 1). Clinical data including days of oxygen requirement, vasoactive 111 drugs, mechanical ventilation, ECMO treatment, and hospitalization days were available for the 112 cohort (Table 1). These values were similar between study groups except for the days in 113 mechanical ventilation. White blood cells and platelet count, ANDV viral load in PBMCs, 114 together with sub-population immunophenotyping of the earliest measurement (up to 48 hours 115 after onset of cardiopulmonary symptoms) were also compared for these groups. There was no 116 difference between groups on viral load, total leukocyte number, or neutrophil percentage, 117 118 although a tendency of increase in viral load and a decrease in leukocyte count was observed in the ECMO/Fatal patients (Table 1). A significant difference was found in platelet count in the 119 two HCPS groups compared to healthy controls, as previously described [24]. The blood 120 121 immune cell populations were evaluated by flow cytometry in the first sample from each patient as described in the methods section. Although no significant difference was found, a trend 122 towards an increase in T helper cells, CD56^{Bright} NK cells and NKT cells, and a tendency for a 123 124 decrease in cytotoxic T cells, NK cells, and B cells was observed in ECMO/Fatal patients compared to MV+VD ones. 125

The complete clinical course of the 12 HCPS patients in this study along with samples obtained is represented in Fig 1. The prodromic phase with non-specific symptoms varied

5

between three to ten days, and day 0 represents the onset of cardiopulmonary symptoms. Blood samples were collected during the acute phase (early acute between the days 0-2 and late acute samples between days 5-6 after the onset of cardiopulmonary symptoms). One last blood sample was collected in the convalescent-phase (day >60 after cardiopulmonary symptoms onset). Patients that only required mechanical ventilation and vasoactive drugs during their hospitalization were grouped in the MV+VD patients group. Patients requiring ECMO or that died were grouped together in the more severe ECMO/Fatal group of patients.

135

136 PBMC transcriptome profile of HCPS patients by severity and clinical phase

137

Total PBMC samples sequenced and analyzed are detailed in S1 Table. Briefly, after 138 quality control filters, 16,187 genes were included in subsequent analyses. First, a 139 multidimensional scaling (MDS) was performed to evaluate the global gene expression patterns 140 141 between the samples to determine which variable explained the difference in the data. In MDS analysis two groups were observed: one integrated by healthy controls and convalescent-phase 142 subjects and another group of acute-phase patients (Fig 2A). These results show that the greatest 143 144 variability in subject's gene expression was produced by the infection itself. Interestingly, there was no clear separation between MV+VD and ECMO/Fatal patients in early or late-acute-phase. 145

Differential gene expression was conducted with the limma-voom analysis workflow using Benjamini and Hochberg (BH) correction for multiple testing. Differential expression analysis was performed by comparing samples from MV+VD and ECMO/Fatal HCPS patients in an early-acute, late-acute, and convalescent-phase with healthy controls. The total of differentially sexpressed genes (DEGs) in the MV+VD group was 277 in early and 109 in late-acute-phase; and

in ECMO/Fatal group DEGs were 310 in early and 342 in late-acute-phase (Fig 2B). IFI27 was 151 the most overexpressed gene with highest Log2FC and lowest p-value in both groups of severe 152 patients during the acute phase. Interestingly, proinflammatory cytokines, such as IL-6 and 153 TNF-a, that are known to be increased in serum of severe HCPS patients, were not differentially 154 expressed in MV+VD or ECMO/Fatal patients at any time when compared to healthy controls. 155 156 Taken together, these results suggest that the increased serum levels of these cytokines could be a contribution of other cell types, such as endothelial cells and macrophages, rather than PBMCs. 157 There were no statistically significant DEGs in the convalescent-phase when compared with 158 healthy controls (Fig 2B). This suggests that at the convalescent-phase, patients have resolved 159 the disease in terms of level of gene expression. At the level of clinical symptoms, some patients 160 continued to be hospitalized because of ECMO complications, others experienced fatigue and 161 mild respiratory distress at day 60, but the majority had returned to normal life. Fig 2C shows the 162 expression profile of MV+VD and ECMO/Fatal HCPS patients at every time point. The total of 163 164 439 DEGs were plotted in the heatmap. ECMO/Fatal patients showed a different signature compared to MV+VD patients during the acute phase in both early and late timepoints. As 165 expected, HCPS patients in the convalescent-phase presented a pattern of expression similar to 166 167 healthy controls. The number of shared and unique DEGs between MV+VD and ECMO/Fatal patients in an early and late acute-phase are shown in a Venn diagram (Fig 2D). There were 58 168 169 genes differentially expressed only in MV+VD patients in an early-acute phase and 2 in a late-acute phase and 52 in ECMO/Fatal patients in an early-acute and 89 in a late-acute phase 170 (Fig 2D). Ninety-one genes were shared throughout all conditions (MV+VD and ECMO/Fatal in 171 172 an early and late-acute phase) compared to healthy controls (Fig 2D).

173

174 Gene set enrichment analysis by severity and clinical phase

175

To further define the biological function and pathways associated with a severe clinical 176 course, we applied a gene set enrichment analysis called blood transcriptome module (BTM) as 177 described [25,26]. BTMs are groups of genes that share a similar function, where BTM up- and 178 downregulation is defined by the percentage of genes within each module that are differentially 179 expressed. Activation of modules was tested comparing each study group to healthy controls and 180 using the FDR-ranked lists of DEGs generated by limma and applying the tmod test. The BTMs 181 with a *p*-value ≤ 0.001 were considered significant. When HCPS patients were analyzed together, 182 a strong upregulation of Modules that group genes with functions in cell cycle, DNA repair, 183 mitosis was observed (data not shown), which can be further observed when patients are 184 re-classified in MV+VD and ECMO/Fatal groups (Fig 3). Moreover, this response is still active 185 during the late-acute-phase but returns to normal values during convalescence. The enrichment 186 187 observed in these pathways points to the immune activation that is taking place in both groups of severe patients and the lymphoid proliferation that is taking place during the acute-phase of the 188 disease. On the other hand, when all HCPS patients were analyzed together, modules that 189 190 grouped genes from the innate immune response were enriched during the early phase of the acute disease (data not shown). When these severe patients were reclassified as MV+VD and 191 192 ECMO/Fatal, this association was only seen in the more severe group (ECMO/Fatal) during the 193 early-acute phase (Fig 3, marked with arrows). These BTMs include a greater activation in antiviral IFN signature, IFN I signalling and innate antiviral response, activation in B cells and 194 plasma cells and BTMS of activated dendritic cells. The comparison of expression of the 195 196 significant genes belonging to these innate immune response marked modules, are shown in S2

197 Table. This data suggests that in ANDV-infected patients that develop HCPS, there is a strong 198 innate immune response that is greater in the most severe ECMO/Fatal HCPS group of patients. 199 Interestingly, these more severe ECMO/Fatal patients have an over-representation of innate 200 immune pathways, especially genes participating in the interferon signaling pathway.

201

202 DEGs in MV+VD and ECMO/Fatal HCPS patients in early-acute phase

203

Once the functions of all DEGs between MV+VD and ECMO/Fatal patients in an 204 early-late acute phase were described, unique genes for each severity group were analyzed. One 205 of the interests of the study was to understand the factors associated with critical clinical courses 206 at the onset of the cardiopulmonary phase, so further analyses were focused on unique DEGs of 207 the early-acute phase. Transcriptional profiles of 110 genes that include 52 genes that were 208 detected to be uniquely differentially expressed in ECMO/Fatal patients and 58 genes detected in 209 MV+VD patients were analyzed. Fig 4 shows a clear difference in the expression profile of 210 these genes between patients of different severities and healthy controls. 211

To evaluate the functions of these unique DEGs, a gene set enrichment analysis was 212 213 performed separately for each group of genes (58 for MV+VD and 52 ECMO/Fatal). This method uses statistical approaches to identify significantly enriched or depleted groups of genes 214 215 that participate in the same biological process. Thus, the functions which are exclusively altered 216 in each group can be identified.No biological processes were found to be enriched in MV+VD patients compared to healthy controls. However, seven biological processes were enriched in 217 ECMO/Fatal patients. These biological processes were mainly from innate immune response, 218 219 primarily type I interferon response (Fig 4B). The detail of the genes belonging to these

biological processes is in the S3 Table. These results showed that genes associated with innate immune response, especially type I interferon response, were enriched only in ECMO/Fatal patients. This is in concordance to what was found on BTM analysis.

223

224 Correlation between expression of BTM enriched exclusively in ECMO/Fatal patients and

225 clinical laboratory data

226

To assess whether the expression of the genes from enriched BTMs in ECMO/Fatal 227 patients in an early-acute-phase could impact the severity and clinical laboratory parameters, the 228 expression of these BTMs was correlated with these patients' laboratory data (Fig 5 and detail in 229 S4 Table). The BTMs associated with interferon response, including antiviral interferon 230 signature (LI.M75), type I interferon response (LI.M127) and innate antiviral response 231 (LI.M150); dendritic cells: activated dendritic cells (LI.M67) and enriched in activated dendritic 232 233 cells (LI.M165); and plasma cells surface signature (LI.S3), showed a statistically positive correlation with ECMO/Fatal clinical course (Fig 5). The BTMs associated with interferon 234 response (LI.M75, LI.M127, and LI.M150) are positively correlated with viral load, amount of 235 236 NK cells and TNF-a serum levels. LI.M127 and LI.M150 are also positively correlated with the amount of NKT cells and IL-6 serum levels and negatively correlated with neutrophils 237 238 percentage. The BTM activated dendritic cells (LI.M67) is positively correlated with NK cells, viral load, amount of NK, and Th cells. Platelets, leukocytes, CD3+, CD8+, CD56 Bright NK cells 239 did not show any statistically significant correlation with the enriched BTMs. Thus, the 240 overexpression of interferon response genes is correlated with a ECMO/Fatal outcome and an 241 242 increased viral load in PBMCs and proinflammatory cytokines (IL-6 and TNF-a) serum levels

and could be contributing to immunopathogenesis instead of restricting viral replication. Having
an increased type I interferon response appears to correlate to poor prognosis in HCPS patients.

246 Discussion

247

The host immune response is an important mechanism in the pathogenesis of HCPS. An exaggerated and uncontrolled activation of the innate and adaptive immune response is associated with severity [20,27–31]. In this study, we applied a transcriptome approach combined with clinical laboratory data to gain a better insight into factors associated with HCPS critical or fatal clinical course.

The human innate immune response, particularly type-I IFN response, is a highly robust and effective first line of defense against virus invasion. In infected and neighboring cells, type I IFNs induce the expression of IFN-stimulated genes (ISGs), the products of which initiate an intracellular antimicrobial program that limits the spread of infectious agents [32,33]. Failure to mount an effective IFN response against the virus leads to systemic infection, while excessive IFN production leads to pathogenicity, severe symptoms, or even fatality [34–36].

Our findings demonstrated that PBMCs transcriptome from the more severe ECMO/Fatal HCPS group of patients have a greater activation of the innate immune response in the earliest stages of the cardiopulmonary phase than in less severe MV+VD patients. BTMs associated with IFN response, dendritic, and plasma cells were enriched in the ECMO/Fatal patients between 0 to 2 days after cardiopulmonary symptoms started. They also had upregulated genes associated with type I interferon response, whose main function is to negatively regulate viral replication (i.e., USP18, ISG15, IFIT3, IFIT1, MX1, IF6, IFI44L, IFITM3 and Siglec-1). In other viral

266 infections, such as Coronavirus disease 19 (COVID-19), severe patients have recently been characterized of having an up-regulation of various ISGs, including ISG15, IFITM1/2/3, and 267 ISG20[31]; so, these unregulated type I IFN responses could be an important hallmark for 268 severity in viral respiratory diseases. Interestingly, the BTMs enriched in the ECMO/fatal HCPS 269 patients associated with type I IFN response (LI.M75, LI.M127, and LI.M150) were positively 270 271 correlated with high viral load, proinflammatory cytokines (IL-6 and TNF-a) serum levels and ECMO/Fatal clinical course. BTM associated with dendritic cells (LI.M67, LI.M165) were also 272 positively correlated with viral load and ECMO/Fatal clinical course. This means that the higher 273 the expression of type I IFN genes, the greater the viral load and proinflammatory response and 274 consequently greater illness severity. Because the overexpression of interferon response genes is 275 associated with a critical and fatal outcome, an increase in viral load in PBMCs and an increase 276 proinflammatory cvtokines serum levels, it could rather be contributing 277 in to immunopathogenesis rather than restricting viral replication in these patients. 278

279 It has been known for decades that viruses evolve different strategies to escape the type I IFN response in order to replicate and disseminate successfully in their hosts [37]. In vitro 280 experiments have shown that pathogenic hantaviruses can block early IFN responses, which 281 282 favor an early viral replication in target cells, but later induce high-level ISG responses (1–4 days after infection) [13,38,39]. These observations correlate with HCPS natural history in which 283 284 there is a long incubation period that can last up to 49 days, and viremia can be detected during 285 this period up to 15 days before symptoms onset, suggesting a long escape of the virus to IFN 286 response.

²⁸⁷ Moreover, *in vivo* experiments have shown that the treatment with IFN- β could increase ²⁸⁸ the survival of Hantaan (HTNV) infected mice only if performed less than 24 hours after

289 infection [40]. In this study we have shown that despite a strong interferon response in the 290 ECMO/fatal HCPS patients, there is no correlation with a decrease in viral load. The findings of 291 this study suggest that insensitivity to the interferon response occurs in ECMO/fatal HCPS 292 patients and correlates with poor prognosis in HCPS patients. The molecular mechanisms by 293 which hantaviruses become insensitive to the interferon response, specifically how they evade 294 the response to ISGs once the infection is already established, is not yet known and should be 295 studied further.

The mechanisms by which type I interferon response promotes severity in viral infections 296 remains controversial and elusive. A common theme is emerging in which type I IFN has the 297 potential to over activate the immune system during acute viral infection. Besides the induction 298 of ISGs, type I IFN also induces secretion of cytokines and chemokines and activation of 299 pathways that allow the clearance of infected cells [41,42]. Therefore, the induction of 300 proinflammatory cytokines or chemokines or activation of apoptosis-inducing pathways to clear 301 302 virally infected cells, which were designed to be protective, can lead to tissue damage with serious consequences to the host [41,43]. HCPS is characterized by an exacerbated immune 303 response that includes a "cytokine storm" that contributes to pathogenesis. In this sense 304 305 increased serum levels of proinflammatory cytokines, such as IL-6, IFN- γ and TNF-a are associated with a severe HCPS outcome [20,22,44]. We found that the overexpression of ISGs is 306 positively correlated with proinflammatory cytokines (IL-6 and TNF-a) serum levels. This 307 suggests that increased type I IFN response could be contributing with the increase of 308 proinflammatory response in the ECMO/fatal HCPS patients. Although these proinflammatory 309 cytokines were not differentially expressed in severe or ECMO/Fatal patients when compared 310 311 with healthy controls, the increased serum levels of these markers could be a contribution from

312 other cell types, such as endothelial cells or macrophages, rather than PBMCs. Thus, the 313 overregulation of ISGs in PBMCs could be contributing to immunopathology altering 314 inflammatory pathways in a paracrine way.

Our results provide insights into the dynamics of early and late PBMCs immune responses 315 in HCPS patients and factors associated with ECMO/fatal clinical course. We found that the 316 317 overexpression of type I IFN genes are positively correlated with increased viral load in PBMCs and proinflammatory cytokines and could contribute to immunopathogenesis rather than 318 restricting viral replication in HCPS patients. Then, hantavirus IFN insensitivity together with 319 exacerbated proinflammatory response induced by increased IFN response could contribute to 320 ECMO/fatal HCPS outcome (Fig 6). These results suggest that treatment with interferon could 321 worsen the HCPS clinical course. Future studies should investigate the damaging effects of type 322 323 I IFN response to better understand the immunopathogenesis of HCPS.

324

325 Materials and methods

326

327 Ethics statement

This study was approved by the ethics committee of each participating institution, Clínica Alemana Universidad del Desarrollo (UDD) IRB4858, FWA8639, January 2016; Hospital Clínico UC, IRB2886, FWA4080, July 2016; Hospital Base Valdivia IRB1914 FWA 3412, January 2017, Hospital Base Osorno IRB1914 FWA 3412, January 2017; Hospital Regional Puerto Montt, IRB1914, FWA 3412, January 2016, Instituto Nacional del Tórax, April 11 2017. Enrolled subjects provided written informed consent, their parents, or legal guardians. Clinical data and stored samples were anonymized to ensure confidentiality.

335

336 Study design

Subjects were recruited in six research centers from central and southern regions of Chile 337 between March, 2017, and June 2018. Hospitalized subjects with a suspected or confirmed 338 diagnosis of ANDV infection by serology or RT-qPCR were invited to participate. Exclusion 339 criteria included patients connected to extracorporeal membrane oxygenation (ECMO) at 340 enrollment. A total of 24 HCPS patients were enrolled, eight were excluded for these analyses: 341 one co-infected with Epstein-Barr virus, another one negatively diagnosed for HCPS, patients 342 with a mild clinical course (not requiring vasoactive drugs or mechanical ventilation) or that did 343 not complete follow up. A group of healthy subjects (controls) were also enrolled (n=9), and 344 exclusion criteria included the presence of chronic disease, pregnancy or any signs and 345 symptoms of an acute infection in the two weeks prior to enrollment. A schematic diagram of 346 enrolled and analyzed patients is available in S1 Fig. The 12 severe HCPS patients analyzed 347 348 were defined as those who develop cardiopulmonary failure and required vasoactive drugs and mechanical ventilation. Severe HCPS patients were further reclassified as MV+VD (n=5) for 349 those who received only mechanical ventilation and vasoactive drugs as treatment and 350 351 ECMO/Fatal (n=7) for those who also received ECMO as a treatment or died. The subjects were followed for sixty days post-enrollment. Two blood samples were collected during the acute 352 phase and one sample in convalescent-phase (at least 60 days after onset of cardiopulmonary 353 354 symptoms). A single sample was taken for healthy controls.

355

356 Sample preparation and RNA-seq

357 The PBMCs were separated by Ficoll-paque (Sigma Aldrich) following the manufacturer's

specifications. Aliquots of 1-3x10⁶ PBMCs/mL were prepared and the RNA was stabilized with 358 RNAprotect cell reagent (QIAGEN) and frozen at -80°C. The RNA was extracted using the 359 RNAeasy kit (Qiagen) following the manufacturer's specifications. The quality was assessed 360 using the Agilent 2200 TapeStation. All samples exhibited RNA integrity numbers (RIN) greater 361 than 6. Aliquots of 350 ng were prepared, stored at -80°C and shipped on dry ice to the Broad 362 363 Institute (Boston, USA) for RNA sequencing. RNA-seq libraries were prepared with Illumina Truseq Stranded mRNA chemistry. Libraries were sequenced in multiplex on the Illumina HiSeq 364 2500 platform in 50M reads in pairs. 365

366

367 Viral Load and multiplex

For the viral load determination, total nucleic acids were extracted from the buffy coat obtained from 5mL of peripheral blood using High Pure Viral Nucleic Acid Kit (Roche) following the manufacturer's specifications. ANDV virus infections were determined by reverse transcription-polymerase chain reaction (RT-qPCR) using primers from the S segment as described previously[45] and the number of viral copies per total ng RNA was calculated. The serum levels of proinflammatory cytokines (IL-6, TNF-a) were measured using a MILLIPLEX map (HCYTOMAG-60K, Merk) following the manufacturer's instructions.

375

376 Transcriptome and BTM analysis

A total of 37 samples from 12 HCPS patients (five MV+VD and seven ECMO/Fatal in an early, and late and convalescent-phase) and nine healthy controls were sequenced (S1 Table). Quality control of the sequenced reads was performed with FastQC. The low-quality sequences (score score <a>30) and Illumina adapters were excluded using trimmomatic (v0.38)[46]. Reads were mapped

to the human genome reference (hg37) using the STAR (v2.7.0d)[47] alignment tool. Read 381 counts per gene were quantified against Ensembl (hg37) transcript reference annotations using 382 featureCounts (v1.6.2)[48]. Analysis was conducted within the Jupyter notebook using IRKernel 383 (v0.8.15) statistical framework. First, filters to remove samples with less than 10 million aligned 384 reads were applied. Only one sample of convalescent-phase from Severe type 1 patient did not 385 386 meet these quality criteria and was excluded from the analyzes. 36 sequenced samples passed filter and were included in the following analysis (S1 Table). Second, RNA-Seq read counts were 387 scaled and normalized by differences in library size between samples using log2-counts per 388 million (log-CPM). Expressed genes were defined as genes with greater than one log-CPM in at 389 least four samples. Genes that did not meet this parameter were filtered. 16,187 genes passed the 390 filter. Third, the RNA-Seq read counts were normalized by composition bias which computes 391 normalization factors for comparing between libraries on a relative scale using the Trimmed 392 Mean of M-values (TMM) method[49] and log2 transformed using voom as previously 393 described[50]. log-CPM and TMM normalizations were performed with edgeR package 394 (v3.24.3)[51]. To assess the similarities and dissimilarities in global expression profile between 395 the samples Multi-dimensional scaling (MDS) was performed by limma package (v3.38.9)[52] 396 397 and plotted by plotMDS function. Differential expression (DE) was conducted with the limma-voom analysis workflow as previously described[50] using Benjamini and Hochberg 398 399 (BH) correction for multiple testing. DE was performed to compare samples from MV+VD 400 early, late and convalescent; and ECMO/Fatal early, late, and convalescent versus healthy controls. Differentially expressed genes (DEGs) were selected based on an adjusted p-value of 401 0.05 (FDR of 5 %) and exhibiting at least 2 log2 fold change (log2FC > 2) a difference in 402 expression levels. To identify the exclusive DEGs on each condition and those shared throughout 403

all conditions a Venn diagram was made using the VennDiagram (v1.6.20) package. The gene set 404 enrichment was performed using the clusterProfiler (v3.14.3). Enriched biological processes with 405 an adjusted p-value of 0.01 were considered statistically significant. The heatmaps were scaled 406 (log2FC median centered) and clusterized by row and graphed by pheatmap package (v. 1.0.12). 407 Blood transcriptome modules (BTM) enrichment analyses were conducted with tmod (v.a40)[53] 408 409 using the tmodLimmaTest function. BTM gene memberships and annotations were obtained from Li et al[25]. BTMs with an adjusted p-value of 0.01 (FDR of 1 %) were considered 410 statistically significant. 411

412

413 Blood immune cell populations

Blood samples (5 ml) were obtained in acid citrate dextrose (ACD) tubes (BD Vacutainer ACD 414 Solution B; BD, Franklin Lakes, NJ) only on early-acute-phase and processed within 2 to 4 hours 415 of collection. PBMCs were separated by Ficoll-paque (Sigma Aldrich) and stored at -80°C using 416 417 CryoStor CS10 medium (STEM CELL technologies) until use. Thawed PBMCs were stained with different antibody panels for characterization of NK, T and B cells subpopulations (S5 418 Table) using BD Biosciences antibodies. PBMCs were rapidly unfrozen and washed with 10% 419 420 FBS supplemented PBS, centrifuged at 1200 rpm, and resuspended in PBS-2% FBS. PBMCs were counted and 2.5-5.0 x 10⁵ live PBMCs were used for antibody stainings. Stainings were 421 performed at room temperature for 15 minutes protected from light. PBMCs viability was 422 423 assessed with the Zombie Aqua Fixable Viability Kit (Biolegend® cat. 423102). After that, unbounded antibodies were washed away two times and stained PBMCs were fixed with 200 uL 424 2% paraformaldehyde. The acquisition was performed in a FACS Canto II flow cytometer (BD 425 426 Biosciences) and the data was analyzed with FlowJo v10.0.7.

427

428 Statistical analysis

RNASeqPower program package (v3.0.1)[54] was used for sample size calculation, which was 429 developed to estimate the statistical power necessary to identify differentially expressed genes 430 from RNA-seq experiments. To estimate the sample size, the estimated power of 0.8, the 431 coefficient of variation of 0.4, and an effect size of 1.75 were used. Considering these 432 parameters, the number of patients required for differential expression analysis was 9 for each 433 group. For the analysis of the patient's demographic and clinical characteristics, IBM SPSS 434 Statistics v.26 was used. Shapiro normality test was applied, and the Mann-Whitney test was 435 used for comparisons between two non-paired numeric variables and Kruskal-Wallis for three or 436 more groups without normal distribution, and Chi-square test for qualitative variables. To assess 437 the correlation between BTM expression and clinical data, the expression median of genes from 438 BTMs for each patient and Log2FC were calculated. Spearman correlation was performed in the 439 R program using cor() function and was graphed with gplots (v3.0.1.1). 440

Acknowledgments: Thank members of the Hantavirus Study Group in Chile who contributed to 441 patient enrollment and follow-up, sample collection and data management are as follows: 442 Catalina Infante, RN, Carolina Henríquez, RN (Departamento de Enfermedades Infecciosas e 443 444 Inmunología Pediátricas, Pontificia Universidad Católica de Chile); Flavio Carrión, PhD, Rodrigo Pérez, BKin (Clínica Alemana de Santiago Universidad del Desarrollo), Pamela Silva, 445 RN, Angélica Gavilán, MT, Iván Rodríguez, MT, Marina Opazo, MD (Hospital Dr, Guillermo 446 447 Grant Benavente Concepción); Carola Osorio, MT, Paulina Miranda, RN, (Hospital Base Valdivia) María Paz Blanco, RN, Camila Bolados, RN, Catherine Bosnich, MT, Paulina 448 449 Cárcamo, MT, Carolina Nuñez, EU (Hospital Puerto Montt Dr. Eduardo Schütz Schroeder);

Felipe Vargas, MT, (Hospital Base San José de Osorno);. Thanks Dr. Anne Bliss and Steven
Bradfute, for critical reading of the manuscript, and Dr. David Gorkin for critical review of the
bioinformatic pipeline. Funding: This research was funded by Fondecyt 1161447, Fondecyt
1201240, Redes 180195, Concurso Interno VRID UDD2018, Facultad de Medicina, Clínica
Alemana Universidad del Desarrollo.

455

456 References:

- Abudurexiti A, Adkins S, Alioto D, Alkhovsky SV, Avšič-Županc T, Ballinger MJ, et al.
 Taxonomy of the order Bunyavirales: update 2019. Arch Virol. 2019;164: 1949–1965.
- Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Mäkelä S, et al. Uncovering the
 mysteries of hantavirus infections. Nat Rev Microbiol. 2013;11: 539–550.

464 4. Martinez VP, Bellomo C, San Juan J, Pinna D, Forlenza R, Elder M, et al. Person-to-person
 465 transmission of Andes virus. Emerg Infect Dis. 2005;11: 1848–1853.

466 5. Núñez JJ, Fritz CL, Knust B, Buttke D, Enge B, Novak MG, et al. Hantavirus Infections
467 among Overnight Visitors to Yosemite National Park, California, USA, 2012. Emerging
468 Infectious Diseases. 2014. pp. 386–393. doi:10.3201/eid2003.131581

- 469 6. Vial PA, Valdivieso F, Mertz G, Castillo C, Belmar E, Delgado I, et al. Incubation period of
 470 hantavirus cardiopulmonary syndrome. Emerg Infect Dis. 2006;12: 1271–1273.
- 471 7. Manigold T, Vial P. Human hantavirus infections: epidemiology, clinical features,
 472 pathogenesis and immunology. Swiss Med Wkly. 2014;144: w13937.
- 473 8. Mertz GJ, Hjelle B, Crowley M, Iwamoto G, Tomicic V, Vial PA. Diagnosis and treatment
 474 of new world hantavirus infections. Curr Opin Infect Dis. 2006;19: 437–442.
- 475 9. Riquelme R, Riquelme M, Torres A, Rioseco ML, Vergara JA, Scholz L, et al. Hantavirus
 476 pulmonary syndrome, southern Chile. Emerg Infect Dis. 2003;9: 1438–1443.
- 477 10. Mackow ER, Gavrilovskaya IN. Hantavirus regulation of endothelial cell functions.
 478 Thromb Haemost. 2009;102: 1030–1041.

Pensiero MN, Sharefkin JB, Dieffenbach CW, Hay J. Hantaan virus infection of human
endothelial cells. J Virol. 1992;66: 5929–5936.

^{461 3.} Ferres M, Vial P, Marco C, Yanez L, Godoy P, Castillo C, et al. Prospective evaluation of
462 household contacts of persons with hantavirus cardiopulmonary syndrome in chile. J Infect
463 Dis. 2007;195: 1563–1571.

481 12. Rowe RK, Pekosz A. Bidirectional virus secretion and nonciliated cell tropism following
482 Andes virus infection of primary airway epithelial cell cultures. J Virol. 2006;80:
483 1087–1097.

Witkowski PT, Bourquain D, Bankov K, Auste B, Dabrowski PW, Nitsche A, et al.
Infection of human airway epithelial cells by different subtypes of Dobrava-Belgrade virus reveals gene expression patterns corresponding to their virulence potential. Virology.
2016;493: 189–201.

14. Nagai T, Tanishita O, Takahashi Y, Yamanouchi T, Domae K, Kondo K, et al. Isolation of
haemorrhagic fever with renal syndrome virus from leukocytes of rats and virus replication
in cultures of rat and human macrophages. J Gen Virol. 1985;66 (Pt 6): 1271–1278.

491 15. Maes P, Clement J, Gavrilovskaya I, Van Ranst M. Hantaviruses: immunology, treatment,
492 and prevention. Viral Immunol. 2004;17: 481–497.

493 16. Markotić A, Hensley L, Daddario K, Spik K, Anderson K, Schmaljohn C. Pathogenic
494 hantaviruses elicit different immunoreactions in THP-1 cells and primary monocytes and
495 induce differentiation of human monocytes to dendritic-like cells. Coll Antropol. 2007;31:
496 1159–1167.

497 17. Raftery MJ, Kraus AA, Ulrich R, Krüger DH, Schönrich G. Hantavirus infection of
498 dendritic cells. J Virol. 2002;76: 10724–10733.

499 18. Marsac D, García S, Fournet A, Aguirre A, Pino K, Ferres M, et al. Infection of human monocyte-derived dendritic cells by ANDES Hantavirus enhances pro-inflammatory state, the secretion of active MMP-9 and indirectly enhances endothelial permeability. Virol J.
2011;8: 223.

503 19. Khaiboullina SF, St Jeor SC. Hantavirus immunology. Viral Immunol. 2002;15: 609–625.

Sondu V, Schrader R, Gawinowicz MA, McGuire P, Lawrence DA, Hjelle B, et al. Elevated
cytokines, thrombin and PAI-1 in severe HCPS patients due to Sin Nombre virus. Viruses.
2015;7: 559–589.

Mori M, Rothman AL, Kurane I, Montoya JM, Nolte KB, Norman JE, et al. High levels of
cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary
syndrome. J Infect Dis. 1999;179: 295–302.

510 22. Maleki KT, García M, Iglesias A, Alonso D, Ciancaglini M, Hammar U, et al. Serum
511 Markers Associated with Severity and Outcome of Hantavirus Pulmonary Syndrome. J
512 Infect Dis. 2019;219: 1832–1840.

S13 23. Ribeiro GE, Leon LE, Perez R, Cuiza A, Vial PA, Ferres M, et al. Deletions in Genes
Participating in Innate Immune Response Modify the Clinical Course of Andes
Orthohantavirus Infection. Viruses. 2019;11. doi:10.3390/v11080680

516 24. López R, Vial C, Graf J, Calvo M, Ferrés M, Mertz G, et al. Platelet Count in Patients with

517 Mild Disease at Admission is Associated with Progression to Severe Hantavirus 518 Cardiopulmonary Syndrome. Viruses. 2019;11. doi:10.3390/v11080693 519 25. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, et al. Molecular signatures of antibody responses derived from a systems biology study of five human 520 521 vaccines. Nat Immunol. 2014;15: 195-204. 522 26. Chaussabel D, Baldwin N. Democratizing systems immunology with modular 523 transcriptional repertoire analyses. Nat Rev Immunol. 2014;14: 271-280. Sane J, Laine O, Mäkelä S, Paakkala A, Jarva H, Mustonen J, et al. Complement activation 524 27 525 in Puumala hantavirus infection correlates with disease severity. Ann Med. 2012;44: 526 468-475. 527 28. Rasmuson J, Pourazar J, Mohamed N, Lejon K, Evander M, Blomberg A, et al. Cytotoxic immune responses in the lungs correlate to disease severity in patients with hantavirus 528 infection. Eur J Clin Microbiol Infect Dis. 2016;35: 713-721. 529 530 29. Ennis FA, Cruz J, Spiropoulou CF, Waite D, Peters CJ, Nichol ST, et al. Hantavirus pulmonary syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin 531 532 Nombre virus nucleocapsid protein isolated during acute illness. Virology, 1997;238: 533 380-390. 534 30. Kilpatrick ED, Terajima M, Koster FT, Catalina MD, Cruz J, Ennis FA. Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus 535 536 pulmonary syndrome. J Immunol. 2004;172: 3297-3304. 537 31. Lee JS, Park S, Jeong HW, Ahn JY, Choi SJ, Lee H, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe 538 539 COVID-19. Sci Immunol. 2020;5. doi:10.1126/sciimmunol.abd1554 540 32. Huang Y, Dai H, Ke R. Principles of Effective and Robust Innate Immune Response to Viral Infections: A Multiplex Network Analysis. Front Immunol. 2019;10: 1736. 541 542 33. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014:14: 36-49. 543 544 34. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, García-Sastre A, et 545 al. Early and sustained innate immune response defines pathology and death in nonhuman 546 primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A. 547 2009;106: 3455-3460. Yockey LJ, Jurado KA, Arora N, Millet A, Rakib T, Milano KM, et al. Type I interferons 548 35. 549 instigate fetal demise after Zika virus infection. Sci Immunol. 2018;3. doi:10.1126/sciimmunol.aao1680 550 551 36. Liu X, Speranza E, Muñoz-Fontela C, Haldenby S, Rickett NY, Garcia-Dorival I, et al. 552 Transcriptomic signatures differentiate survival from fatal outcomes in humans infected

- with Ebola virus. Genome Biol. 2017;18: 4.
- Beachboard DC, Horner SM. Innate immune evasion strategies of DNA and RNA viruses.
 Curr Opin Microbiol. 2016;32: 113–119.
- 556 38. Geimonen E, Neff S, Raymond T, Kocer SS, Gavrilovskaya IN, Mackow ER. Pathogenic
 and nonpathogenic hantaviruses differentially regulate endothelial cell responses. Proc Natl
 Acad Sci U S A. 2002;99: 13837–13842.
- Matthys V, Mackow ER. Hantavirus regulation of type I interferon responses. Adv Virol.
 2012;2012: 524024.
- Tamura M, Asada H, Kondo K, Takahashi M, Yamanishi K. Effects of human and murine
 interferons against hemorrhagic fever with renal syndrome (HFRS) virus (Hantaan virus).
 Antiviral Res. 1987;8: 171–178.
- 41. Goritzka M, Durant LR, Pereira C, Salek-Ardakani S, Openshaw PJM, Johansson C.
 Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine
 production in the lung during respiratory syncytial virus infection. J Virol. 2014;88:
 6128–6136.
- 568 42. Davidson S, Maini MK, Wack A. Disease-promoting effects of type I interferons in viral,
 569 bacterial, and coinfections. J Interferon Cytokine Res. 2015;35: 252–264.
- 570 43. Davidson S, Crotta S, McCabe TM, Wack A. Pathogenic potential of interferon αβ in acute
 571 influenza infection. Nat Commun. 2014;5: 3864.
- 44. Angulo J, Martínez-Valdebenito C, Marco C, Galeno H, Villagra E, Vera L, et al. Serum
 levels of interleukin-6 are linked to the severity of the disease caused by Andes Virus. PLoS
 Negl Trop Dis. 2017;11: e0005757.
- 575 45. Vial C, Martinez-Valdebenito C, Rios S, Martinez J, Vial PA, Ferres M, et al. Molecular
 576 method for the detection of Andes hantavirus infection: validation for clinical diagnostics.
 577 Diagn Microbiol Infect Dis. 2016;84: 36–39.
- 46. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence
 data. Bioinformatics. 2014;30: 2114–2120.
- 580 47. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast
 universal RNA-seq aligner. Bioinformatics. 2013;29: 15–21.
- 48. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for
 assigning sequence reads to genomic features. Bioinformatics. 2014;30: 923–930.
- 49. Robinson MD, Oshlack A. A scaling normalization method for differential expression
 analysis of RNA-seq data. Genome Biol. 2010;11: R25.
- 586 50. Law CW, Alhamdoosh M, Su S, Dong X, Tian L, Smyth GK, et al. RNA-seq analysis is

587		easy as 1-2-3 with limma, Glimma and edgeR. F1000Res. 2016;5.				
588		doi:10.12688/f1000research.9005.3				
	51.	Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential				
590		expression analysis of digital gene expression data. Bioinformatics. 2010;26: 139–140.				
591	52.	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential				
592		expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res.				
593		2015;43: e47.				
504	50	Weinen I 2nd Democratic T touch an D no dece fan en en le demokier eiste en idemok				
594 595	53.	Weiner J 3rd, Domaszewska T. tmod: an R package for general and multivariate enrichment analysis. PeerJ Preprints. 2016;4. Available:				
595 596		https://pure.mpg.de/rest/items/item 2404004/component/file 2404003/content				
0,00		https://pure.htpg.ue/resultenis/item_2101001/component/ine_2101005/content				
597	54.	Hart SN, Therneau TM, Zhang Y, Poland GA, Kocher J-P. Calculating sample size				
598		estimates for RNA sequencing data. J Comput Biol. 2013;20: 970-978.				
599						
222						
600						
601	Sup	porting Information captions				
602						
603	S1 I	Fig. Schematic overview of enrolled and analyzed individuals for this study.				
604						
605	05 S1 Table. Number of sequenced samples of HCPS patients and Healthy controls.					
606						
607						
608	S2]	Table. Significant DEGs belonging to marked BTMs from text Fig 3				
609						
610	S3	Table. Gene enrichment analysis: Biological processes and enriched genes in				
611	ECI	MO/Fatal group of patients in early-acute-response, from Fig 4B				
612						
613		Table. Correlations between transcriptional profile enriched in ECMO/Fatal patients in				
614	an e	early acute response and clinical data.				
615						
		Table. Cell surface markers used to define WBC populations by flow cytometry				
617		Table. Cell surface markers used to define WBC populations by flow cytometry nunophenotyping.				
617 618	imn	nunophenotyping.				
617 618 619	imn Dat	a reporting: FastQ files from transcriptomic analysis are available at PRJNA660433. Any				
617 618 619	imn Dat	nunophenotyping.				
617 618 619 620	imn Dat met	a reporting: FastQ files from transcriptomic analysis are available at PRJNA660433. Any				

Investigación y Desarrollo (ANID) Projects Fondecyt 1161447, Fondecyt 1201240, Redes
180195; Concurso Interno VRID UDD2018, Universidad del Desarrollo.

624 **Competing interests:** The authors declare no conflict of interest.

625

- 626 **Related manuscripts:** The authors declare there is not a duplicated or related manuscript under
- 627 consideration or accepted for publication elsewhere.
- 628 Author contributions: Conceptualization C.V., P.V. and G.E.; methodology C.V., L.L. and GE;
- 629 patient enrollment M.F., N.LC., C.M-V., L.F, M.L.R, J.G., F.A., J.G., R.L., J.L.P; formal analysis,
- 630 G.E. and L.L.; investigation, R.P., E.D., C.M-V., P.V., A.C.; resources, P.V. and C.V.; data
- 631 curation, A.C.; writing original draft preparation, G.E, C.V. and L.L., writing review and editing,
- N.LC., M.C., G.M. and P.V.; project administration, R.P.; funding acquisition, G.M., P.V. and C.V.

634

635

636

	HCPS – Severe Patients			
	MV+VD	ECMO/Fatal	Healthy Controls	P value
No. of patients	5	7	9	
Age (years), Median (25 to 75% IQR)	22 (10.0-26.50)	34 (15-36)	25 (17.0-40.50)	0.501 ^a
Gender, n (%)				
Male	5 (100)	4 (44.4)	5 (55.6)	0.193 ^b
Female	0	3 (37.5)	4 (44.4)	
Ethnicity, n (%)				
European	4 (80)	5 (71.4)	8 (88.9)	0.676 ^b
Amerindian	1 (20)	2 (28.6)	1 (11.1)	
Days of prodromal				
symptoms, Median (25 to 75% IQR)	6 (4.5-7.0)	6 (5.0-7.0)	NA	1.000 °
Days of Oxygen requirement	6 (2.0-7.5)	10 (4.0-19.0)	NA	0.149 °
Days of VD duration	3 (2.0-3.5)	7 (1.0-9.0)	NA	0.202 °
Days of MV duration	4 (3.0-5.5)	9 (4.0-16.0)	NA	0.106 °
Days of ECMO	0	4 (0-6.0)	NA	0.048 °
Days of Hospitalization	13 (9.5-21.5)	19 (4.0-59.0)	NA	0.876 °
	· · · · · · · · · · · · · · · · · · ·	atory exams ^d		
ANDV Viral Load	319.50	616	NT A	0.296.6
(copies/ng RNA)	(82-557)	(285.5-3368.25)	NA	0.286 °
Platelets (cells/mm ³)	44500 (33250-51250)	79000 (47750-154500)	236000 (201500-253000)	0.002 ª
Leukocytes (cells/mm3)	14900 (10000-22300)	10850 (7175-15425)	6400 (5725-7575)	0.085 ª
Neutrophils %	51 (47-60.47)	63.8 (37.03-81)	53 (51-61)	0.732 ^a
	Blood cell in	nmunophenotype*		
T cell panel				
(cells/mm3)				
CD3+ cells	734.97 (568.2-2384.37)	1216.39 (443.99-3390.33)	1234.33 (1018.27-1575.23)	0.866 ^a
CD4+ T helper cells	130.08 (114.87-419.53)	481.82 (197.12-1920.69)	926.42 (692.69-1308.09)	0.90 ^a
CD8+ cytotoxic T cells	633.95 (452.5-1977.55)	736.34 (246.51-1194.27)	302.99 (262.94-336.84)	0.297 ª
NK cell panel (cells/mm3)				
CD56+ NK cells	83.85 (60.01-199.09)	462.45 (110.19-1243.82)	290.96 (191.72-763.20)	0.258 ª

Table 1. Demographics, clinical and blood cells immunophenotypes of HCPS patients and healthy controls.

CD3- CD56+	2.26	45.97	17.52	0.098 ^a
NK Bright cells	(1.62-8.40)	(7.73-132.95)	(10.11-24.23)	
CD3+ CD56+	67.39	96.73	42.62	0.753 °
NKT cells	(37.92-82.22)	(19.76-117.53)	(30.10-141.45)	
B cell panel (cells/mm3)				
CD19+ LB cells	122.85 (94.18-411.87)	169 (84.29-731.69)	364.27 (211.37-421.74)	0.508 °

Abbreviations: HCPS, hantavirus cardiopulmonary syndrome; NA, not applicable; VD, vasoactive drugs; MV, mechanical ventilation; ECMO, extracorporeal membrane oxygenation; LOS, length of stay; n, number; LB, B lymphocytes. *Data shown represent the median (25 to 75% IQR) of the first sample from 12 HCPS, 5 VM+VD, 7 ECMO/Fatal and 9 Healthy controls; ^aKruskal-Wallis test and ^b Chi-square test were used for comparisons between VM+VD, ECMO/Fatal, and healthy controls; ^cMann-Whitney test was used for comparisons between VM+VD and ECMO/Fatal. ^d Data shown represents the median (25 to 75% IQR) of the first sample of each patient (Day 0-2/Early acute).





Fig. 1. Clinical course of severe HCPS patients. Y axis is patient ID, X axis are the days of evolution, with a highlight on disease timeline: early-acute, late-acute or convalescent phase. Light green bars are the days of onset of nonspecific symptoms. Day 0 represents onset of cardiopulmonary symptoms. Blue bars represent the days when patients required supplementary oxygen. Red bars represent days when patients developed HCPS, requiring vasoactive drugs and mechanical ventilation as treatment. Dark green bars represent patients requiring ECMO. Patients that required ECMO or died were sub-cathegorize to the ECMO/Fatal group. Less severe patients that required vasoactive drugs and mechanical ventilation were sub-cathegorize to VM+VD patients. Grey bars are the hospitalization days to recover. *samples taken, † patients who died. VD, vasoactive drugs; MV, mechanical ventilation; ECMO, extracorporeal membrane oxygenation.



36 samples

Fig. 2. Transcriptional PBMC signature of HCPS patients by severity. (A) HCPS patients and healthy controls were divided in seven study groups from A to G (study groups inside figure legend). Transcriptional profile was graphed as a multidimensional scaling (MDS) plot, where X and Y axis represents the variability in global expression profile of the samples and each dot is a patient with the corresponding colour of the study group. (B) Number of differentially expressed genes (DEGs) between MV+VD and ECMO/Fatal HCPS patients in an early-late-convalescent phase versus healthy controls with adjusted p-value of 0.05 (FDR of 5 %) and exhibiting at least 2 log2 fold change (log2FC > 2) difference in expression levels. DEGs were obtained by comparing each study group of HCPS patients with the healthy control group. (C) Transcriptional signatures of DEGs of healthy controls, MV+VD and ECMO/Fatal HCPS patients in an early and late-acute and convalescent phase. Data are displayed in a heatmap format, where each column represents a patient and each row represents the expression value (log2FC median centered) of each gene between all samples. Red indicates overexpression, blue indicates underexpression, and yellow indicates no difference in expression between samples. The total of DEGs between groups were plotted in the heatmap (439 transcripts). (D) The Venn diagram shows the number of shared and unique DEGs between MV+VD and ECMO/Fatal patients in an early and late-acute-phase versus healthy controls.




Fig. 3. Dynamics of VM+VD and ECMO/Fatal HCPS patient's response in PBMCs. BTM dot plot of differentially enriched BTMs in VM+VD and ECMO/Fatal HCPS patients, in early-late-convalescent-phases were compared with healthy controls. Y axis has the name and code of each BTM module, and X axis each study group. Activation of modules was tested using the FDR-ranked lists of genes generated by limma and applying the tmod test. Each comparison is in the intersection of lines of the X and Y axis. When a module is statistically significant (p-value ≤ 0.001) it is represented by a pie chart in the intersection in which the proportion of significantly upregulated genes are shown in red and downregulated in blue. The grey portion of the pie represents genes that were not significantly differentially regulated. The effect size (enrichment) is proportional to its size which means that the larger the size of the pie, the greater the module enrichment. The significance of module activation (*p-value*) is proportional to the intensity of the color pie, which means that the greater the color intensity (stronger the red or blue color), the lower the *p-value* and the greater the significance. Modules that were not statistically significant, were not plotted and are seen as the line cross of X and Y axis.




Fig. 4. Transcriptional profile of DEGs in VM+VD and ECMO/Fatal patients in an early-acute phase. (A). A total of 110 transcripts are displayed in a heatmap format, where each column represents the gene expression of a patient (five VM+VD, seven ECMO/Fatal and nine healthy controls); Each row represents expression value (log2FC median centered) for each gene between all samples First row corresponds to the colour of the study group (legend inside the figure). Red indicates overexpression, blue indicates underexpression, and yellow indicates no difference in expression between samples. (B) Results of biological processes enriched in ECMO/Fatal patients. Gene set enrichment analysis was performed for the 52 exclusive DEG in ECMO/Fatal patients in an early-acute-phase. Node size correlates with gene set size and edge widths indicate the number of shared genes. Red and blue color indicate more and less enrichment significance respectively.




Fig. 5. Correlations between transcriptional profile enriched in ECMO/Fatal patients in an early acute response and clinical laboratory data. X axis has clinical, laboratory data and immune profile information Y axis has the code of analyzed BTMs and to which biological process it belongs. Spearman correlation between expression median of genes over- or underexpressed per BTM data and clinical/lab/immune information was performed for VM+VD and ECMO/Fatal patients. The dot in the intersection of X and Y axis shows the correlation, if no dot is present there's no correlation. The intensity of the color in the dot indicates the strength of the Spearman's correlation coefficient (red positive correlation and blue negative correlation), and the dot size indicates the significance of the *P-value*. CD3, CD3+ cells; CD4+, T helper cells; CD8+, cytotoxic T cells; LB, B cells; LI.M75, antiviral interferon signature; LI.M127, type I interferon response; LI.M150, innate antiviral response; LI.M67, activated dendritic cells; LI.S3, plasma cells surface signature.




Fig. 6. Increased type I IFN is a hallmark of disease severity in HCPS patients. After infection is established in an early-acute-phase, type I IFN response is expressively activated and insensitivity to IFN can happen in the more severe patients that are treated with ECMO or die. Also, other cells such as endothelial cells produce high levels of proinflammatory cytokines that contribute to exacerbated immune response in more severe patients. Less severe patients present a moderate interferon response which leads to an antiviral and controlled immune response. Created with Biorender.